| Aug 8 |
X4 Pharmaceuticals GAAP EPS of $0.45 beats by $0.46
|
| Aug 8 |
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
|
| Aug 7 |
X4 Pharmaceuticals Q2 2024 Earnings Preview
|
| Jul 30 |
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
|
| Jul 8 |
XFOR: Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients…
|
| Jul 2 |
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
|
| Jun 27 |
X4 slips after mid-stage data for lead drug in neutropenia
|
| Jun 27 |
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
|
| Jun 24 |
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
|
| Jun 3 |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
